Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

ACTG has launched A5374, a Phase I/IIa clinical trial to evaluate the safety, tolerability, and antiviral effect of a ...

head of the HIV Prevention Trials Network says there are four areas of research which are being investigated in HIV; ...

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

[2] Measures of effectiveness include pregnancy rate per treatment cycle, cumulative clinical pregnancy rate (CCPR) and cumulative live-birth rate (CLBR), while rates of HIV seroconversion and ...

A study of nearly 1,000 gay male couples in The Lancet found no cases of HIV transmission over eight years. This was due to treatment reducing the virus to very low levels in the body.

Treatment for HIV/AIDS has consistently seen progress each ... The results of the iPrEx study were released in 2010, finding that a daily dose of HIV drugs reduced the risk of HIV infection ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Blog - allAfrica's Sethi Ncube is in Lima, Peru, for the 5th HIV Research for Prevention Conference, HIVR4P 2024, reporting ...

The national HIV prevalence was 16. 3% among adults aged 15 years and older, translating to an estimated 7. 4 million adults ...

After 37 years of pioneering health journalism, community engagement, and empowerment through information, we have now ceased operations. This website will be accessible until September 2025, with all ...